Estimado(a) Dr.(a) le invitamos a ver la infografía “Efecto de los análogos de GLP-1 sobre la resistencia a la insulina”
Por la Dra. Ruth Carmina Cruz Soto. Especialista en Endocrinología, Obesidad y Trastornos de la Conducta Alimentaria. Cédula 8567382.
Para descargar la infografía haga clic aquí.
Referencias
- Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018 Jul;14(7):390-403
- Rakipovski G, Rolin B, Nøhr J, Klewe I, Frederiksen KS, Augustin R, et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosisin ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways. JACC Basic Transl Sci. 2018 Nov 21;3(6):844-857.
- Moellmann J, Klinkhammer BM, Onstein J, Stöhr R, Jankowski V, et al. Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy. Diabetes. 2018 Nov;67(11):2410-2419
- Alicic RZ, Cox EJ, Neumiller, J. et al. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nat Rev Nephrol. 2021; 17, 227–244.
- Gribble FM, Reimann F. Metabolic Messengers: glucagon-like peptide 1. Nat Metab 3. 2021;142–148.
- Yaribeygi H, Sathyapalan T, Sahebkar A. Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity. Life Sci. 2019 Oct 1;234:116776.
- Sandoval D, Sisley SR. Brain GLP-1 and insulin sensitivity. Mol Cell Endocrinol. 2015 Dec 15;418 Pt 1:27-32.
- Jinnouchi H, Sugiyama S, Yoshida A, Hieshima K, Kurinami N, Suzuki T, et al. Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Res. 2015;2015:706416.
- Fonseca VA, Capehorn MS, Garg SK, Jódar Gimeno E, Hansen OH, Holst AG, et al. Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. J Clin Endocrinol Metab. 2019 Apr 2:jc.2018-02685
Material desarrollado con fines de educación médica continua.
Material exclusivo para profesionales de la salud.
La información aquí presentada es opinión del ponente.
Código interno de aprobación: MX22NNG00009.
